|
BCAR1 |
BCAR1 scaffold protein, Cas family member |
- Downstream signal transduction
- p130Cas linkage to MAPK signaling for integrins
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
|
|
|
BCCIP |
BRCA2 and CDKN1A interacting protein |
|
|
|
|
BCR |
BCR activator of RhoGEF and GTPase |
- Signaling by cytosolic FGFR1 fusion mutants
- Signaling by FGFR1 in disease
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RAC3 GTPase cycle
|
- Imatinib
- Dasatinib
- Bosutinib
- Ponatinib
|
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
- Chronic myeloid leukemia (CML)
|
|
BMX |
BMX non-receptor tyrosine kinase |
- Apoptotic cleavage of cellular proteins
- Synthesis of PIPs at the plasma membrane
|
- Fostamatinib
- Zanubrutinib
|
|
|
BRMS1 |
BRMS1 transcriptional repressor and anoikis regulator |
- HDACs deacetylate histones
- Potential therapeutics for SARS
|
|
|
|
CA3 |
carbonic anhydrase 3 |
- Reversible hydration of carbon dioxide
|
- Topiramate
- Ethoxzolamide
- Sulpiride
- Celecoxib
- Benzthiazide
- Valdecoxib
- Cyclothiazide
- Methazolamide
- Acetazolamide
- Dorzolamide
- Zonisamide
- Diclofenamide
- Brinzolamide
- Ellagic acid
- Saccharin
|
|
|
CASP8 |
caspase 8 |
- Apoptotic cleavage of cellular proteins
- Caspase activation via Death Receptors in the presence of ligand
- NOD1/2 Signaling Pathway
- TRIF-mediated programmed cell death
- Caspase-mediated cleavage of cytoskeletal proteins
- Regulation by c-FLIP
- RIPK1-mediated regulated necrosis
- CASP8 activity is inhibited
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- CLEC7A/inflammasome pathway
- Regulation of necroptotic cell death
- Dimerization of procaspase-8
- Activation, myristolyation of BID and translocation to mitochondria
- Apoptotic execution phase
- FasL/ CD95L signaling
- TRAIL signaling
- TLR3-mediated TICAM1-dependent programmed cell death
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- Microbial modulation of RIPK1-mediated regulated necrosis
- Defective RIPK1-mediated regulated necrosis
- Regulation of NF-kappa B signaling
|
- Trichostatin A
- AN-9
- Bryostatin 1
- Bardoxolone
- Oleandrin
|
- Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
|
|
CAV1 |
caveolin 1 |
- Triglyceride catabolism
- eNOS activation
- NOSTRIN mediated eNOS trafficking
- Thyroxine biosynthesis
- Basigin interactions
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- VEGFR2 mediated vascular permeability
- RHOA GTPase cycle
- Extra-nuclear estrogen signaling
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOQ GTPase cycle
- RHOH GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RAC3 GTPase cycle
- RHOF GTPase cycle
- FOXO-mediated transcription of cell cycle genes
- RND3 GTPase cycle
- RND2 GTPase cycle
- RND1 GTPase cycle
- SARS-CoV-1 targets host intracellular signalling and regulatory pathways
- SARS-CoV-2 targets host intracellular signalling and regulatory pathways
|
|
- Congenital generalized lipodystrophy (CGL)
|
|
CAV2 |
caveolin 2 |
- Extra-nuclear estrogen signaling
|
|
|
|
CBL |
Cbl proto-oncogene |
- Interleukin-6 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Spry regulation of FGF signaling
- Regulation of KIT signaling
- EGFR downregulation
- TGF-beta receptor signaling activates SMADs
- Constitutive Signaling by EGFRvIII
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Negative regulation of MET activity
- PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- InlB-mediated entry of Listeria monocytogenes into host cell
- InlB-mediated entry of Listeria monocytogenes into host cell
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Signaling by CSF1 (M-CSF) in myeloid cells
- Negative regulation of FLT3
- FLT3 signaling by CBL mutants
|
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
CBLC |
Cbl proto-oncogene C |
|
|
|
|
CCDC180 |
coiled-coil domain containing 180 |
|
|
|
|
CCNA1 |
cyclin A1 |
- G0 and Early G1
- Telomere Extension By Telomerase
- Cdc20:Phospho-APC/C mediated degradation of Cyclin A
- Regulation of APC/C activators between G1/S and early anaphase
- SCF(Skp2)-mediated degradation of p27/p21
- Senescence-Associated Secretory Phenotype (SASP)
- DNA Damage/Telomere Stress Induced Senescence
- Ub-specific processing proteases
- Processing of DNA double-strand break ends
- TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- G2 Phase
- Orc1 removal from chromatin
- CDK-mediated phosphorylation and removal of Cdc6
- G1/S-Specific Transcription
- Cyclin A/B1/B2 associated events during G2/M transition
- G2/M DNA replication checkpoint
- p53-Dependent G1 DNA Damage Response
- Cyclin A:Cdk2-associated events at S phase entry
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
|
|
|
|
CD2AP |
CD2 associated protein |
- Nephrin family interactions
|
|
- Nephrotic syndrome and focal segmental glomerulosclerosis
|
|
CD33 |
CD33 molecule |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Neutrophil degranulation
|
- Gemtuzumab ozogamicin
- AVE9633
|
|
|
CD36 |
CD36 molecule (CD36 blood group) |
- Platelet degranulation
- Cross-presentation of particulate exogenous antigens (phagosomes)
- ER-Phagosome pathway
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- Toll Like Receptor TLR6:TLR2 Cascade
- PPARA activates gene expression
- Scavenging by Class B Receptors
- Scavenging by Class B Receptors
- Transcriptional regulation of white adipocyte differentiation
- Intracellular metabolism of fatty acids regulates insulin secretion
- MyD88 deficiency (TLR2/4)
- IRAK4 deficiency (TLR2/4)
- Regulation of TLR by endogenous ligand
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
|
|
|
|
CD44 |
CD44 molecule (IN blood group) |
- Degradation of the extracellular matrix
- Cell surface interactions at the vascular wall
- Hyaluronan metabolism
- Integrin cell surface interactions
- Hyaluronan degradation
- Neutrophil degranulation
- Interferon gamma signaling
- Developmental Lineage of Mammary Gland Luminal Epithelial Cells
- Developmental Lineage of Mammary Gland Myoepithelial Cells
- Developmental Lineage of Mammary Stem Cells
|
- Bivatuzumab
- Hyaluronic acid
|
|
|
CD46 |
CD46 molecule |
- Regulation of Complement cascade
|
|
|
|
CD47 |
CD47 molecule |
- Cell surface interactions at the vascular wall
- Integrin cell surface interactions
- Signal regulatory protein family interactions
- Signal regulatory protein family interactions
- Neutrophil degranulation
|
|
|
|
CD59 |
CD59 molecule (CD59 blood group) |
- COPII-mediated vesicle transport
- Cargo concentration in the ER
- Neutrophil degranulation
- COPI-mediated anterograde transport
- Regulation of Complement cascade
|
|
- Complement regulatory protein defects, including the following six diseases: C1 inhibitor deficiency (hereditary angioedema); C4 binding protein alpha deficiency; C4 binding protein beta deficiency; Factor I deficiency; Decay-accelerating factor (CD55) deficiency; CD59 deficiency
|